NDC 50742-397-01 - Buprenorphine and Naloxone
This NDC is not currently matched to an FDA NDC product listing in FDA.report, but it is a valid NDC-form code. FDA.report is showing the available DailyMed label context for the product root.
- Product NDC
- 50742-397
- Requested NDC
- 50742-397-01
- Package NDCs from labels
- 50742-397-01, 50742-397-30
- Manufacturer
- Redpharm Drug
- Effective date
- 2026-04-22
- Current FDA listing
- Not matched in FDA.report NDC product tables
DailyMed Labels#
| Label | Manufacturer | Effective date | Type |
|---|---|---|---|
| Buprenorphine and Naloxone - Redpharm Drug | Redpharm Drug | 2026-04-22 | HUMAN PRESCRIPTION DRUG LABEL |
| ACESULFAME POTASSIUM - INGENUS PHARMACEUTICALS, LLC | DifGen Pharmaceuticals LLC | Aveva Drug Delivery Systems, Inc | INGENUS PHARMACEUTICALS, LLC | DifGen Pharmaceuticals LLC | Aveva Drug Delivery Systems, Inc | 2026-03-23 | HUMAN PRESCRIPTION DRUG LABEL |
DailyMed Package Descriptions#
| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|---|---|---|---|---|---|
| 50742-397-01 | Buprenorphine and Naloxone | 1 in 1 POUCH | FILM | 1 | 6 | |
| 50742-397-30 | Buprenorphine and Naloxone | 30 in 1 CARTON | FILM | 30 | 6 |
DailyMed Dashboard NDC Coverage#
DailyMed Billing Units#
| Package NDC | Billing unit | Product NDC | DailyMed indexing SPL | SPL version | Effective |
|---|---|---|---|---|---|
| 50742-397-01 | EA - Each | 50742-397 | aa4c2b07-0699-49cf-8d69-6c63a89e993c | 1 | 2025-06-13 |
| 50742-397-30 | EA - Each | 50742-397 | 42327cd3-42ee-452c-af20-917e6d8eac80 | 1 | 2025-06-13 |
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| Naloxone Hydrochloride | NALOXONE HYDROCHLORIDE | Sina Health Inc | 2879294f-9af9-459e-e063-6394a90a0820 | 2026-01-12 | Warnings, Adverse reactions | F850569PQR |
| Buprenorphine and Naloxone | BUPRENORPHINE AND NALOXONE | Dr.Reddys Laboratories Inc | 718756d7-0131-b173-6c45-5ee039b311b0 | 2026-01-12 | Warnings, Adverse reactions | 1010604 1010600 56W8MW3EN1 |
| Buprenorphine and Naloxone | BUPRENORPHINE AND NALOXONE | Dr.Reddys Laboratories Inc | 72dc1ec0-7c59-a587-4ffd-c40ef79e6fb2 | 2026-01-12 | Warnings, Adverse reactions | 1307056 1307061 56W8MW3EN1 |
| Enviro Detox 6009 | ENVIRO DETOX | Professional Complementary Health Formulas | a6aab63a-9313-4490-b3a4-0b08f7753cc5 | 2026-01-08 | Warnings | 5138Q19F1X |
| Buprenorphine | BUPRENORPHINE | AvPAK | 1408cd8f-a0b5-6be7-e063-6394a90a0b41 | 2026-01-08 | Warnings, Adverse reactions | 56W8MW3EN1 |
| Buprenorphine HCl and Naloxone HCl | BUPRENORPHINE AND NALOXONE | AvPAK | b955054b-b37d-4079-4fed-5939b763ecb4 | 2026-01-08 | Warnings, Adverse reactions | 56W8MW3EN1 |
| Cell Energy Performance Drops 2048 | CELL ENERGY PERFORMANCE DROPS | Professional Complementary Health Formulas | 8701ea61-5d5f-466b-8d2c-f808e7b4d8fe | 2026-01-08 | Warnings | XF417D3PSL |
| Metab 6012 | METAB | Professional Complementary Health Formulas | f3576d6f-c9ab-4370-8a32-b6c4bf6ba4fd | 2026-01-08 | Warnings | XF417D3PSL |
| Herbal Diuretic Liquescence 3011 | HERBAL DIURETIC LIQUESCENCE | Professional Complementary Health Formulas | 5eee7f21-a3c4-46e0-a642-a4ca635734e3 | 2026-01-08 | Warnings | XF417D3PSL |
| NALOXONE HYDROCHLORIDE | NALOXONE HYDROCHLORIDE | Padagis Israel Pharmaceuticals Ltd | b5d40220-f194-4835-b70c-f304ecb222d5 | 2026-01-06 | Warnings | F850569PQR |
| BELBUCA | BUPRENORPHINE HYDROCHLORIDE | BioDelivery Sciences International Inc | bc2b7a3d-72cf-497c-95b0-ba2b71f63c64 | 2026-01-02 | Boxed warning, Warnings, Adverse reactions | 56W8MW3EN1 |
| Naloxone Hydrochloride | NALOXONE HYDROCHLORIDE | Dr. Reddy's Laboratories, Inc. | b1303f15-c48b-a44d-b28a-72f370094e02 | 2026-01-01 | Warnings, Adverse reactions | F850569PQR |
| Buprenorphine and Naloxone Sublingual Film | BUPRENORPHINE AND NALOXONE | Alvogen Inc. | 4210afeb-474c-d842-d68e-af7e0021851a | 2026-01-01 | Warnings, Adverse reactions | 1307056 1307061 1010604 1010600 56W8MW3EN1 |
| Buprenorphine Hydrochloride | BUPRENORPHINE HYDROCHLORIDE | Hospira, Inc. | 23aa1bb3-cecf-4e62-29bb-48488bb66fc3 | 2025-12-31 | Boxed warning, Warnings, Adverse reactions | 56W8MW3EN1 |
| Buprenorphine and Naloxone Sublingual Film | BUPRENORPHINE AND NALOXONE | Redpharm Drug | 2fd16916-95a9-14b5-e063-6294a90a79fa | 2025-12-27 | Warnings, Adverse reactions | 1010604 56W8MW3EN1 |
| Zubsolv | BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE | Orexo US, Inc. | 5f5cfcfe-d52b-49e6-8fe4-550477332dd2 | 2025-12-27 | Warnings, Adverse reactions | F850569PQR 56W8MW3EN1 |
| Naloxone Hydrochloride | NALOXONE HYDROCHLORIDE | BPI Labs LLC | 5de44ee7-6525-4857-9a67-8882e96dbeb5 | 2025-12-26 | Warnings, Adverse reactions | F850569PQR |
| Buprenorphine HCl | BUPRENORPHINE HCL | Redpharm Drug | 301eaed5-8499-ad95-e063-6294a90a58f5 | 2025-12-23 | Warnings, Adverse reactions | 56W8MW3EN1 |
| Suboxone | BUPRENORPHINE HYDROCHLORIDE, NALOXONE HYDROCHLORIDE | INDIVIOR INC. | 8a5edcf9-828c-4f97-b671-268ab13a8ecd | 2025-12-22 | Warnings, Adverse reactions | 1307056 1307061 1010604 1010600 F850569PQR 56W8MW3EN1 |
| Sterile Cord Blood Collection Unit (MSC128D) | ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE SOLUTION | Maco Productions | 251fd4cb-4aa4-4473-9f89-968da856eb77 | 2025-12-18 | Warnings | 1Q73Q2JULR |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.